[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

Year

Day

May 29, 2020
Original Investigation

FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. Published online May 29, 2020. doi:10.1001/jamaoncol.2020.2020

This phase 2 nonrandomized clinical trial evaluates the clinical activity and safety of the FOLFIRINOX regimen (leucovorin, fluorouracil, irinotecan, and oxaliplatin) as first-line treatment for patients with advanced gastroesophageal adenocarcinoma.

Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up

Abstract Full Text
free access
JAMA Oncol. Published online May 29, 2020. doi:10.1001/jamaoncol.2020.2091

This secondary analysis evaluates the effect of adjuvant imatinib on overall survival in patients who have a high estimated risk for gastrointestinal stromal tumor recurrence after macroscopically complete surgery.

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. Published online May 29, 2020. doi:10.1001/jamaoncol.2020.2218

This randomized clinical trial examines the effect of savolitinib monotherapy compared with sunitinib monotherapy on progression-free survival in patients with MET-driven, unresectable and locally advanced, or metastatic papillary renal cell carcinoma.

Brief Report

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma

Abstract Full Text
free access
JAMA Oncol. Published online May 29, 2020. doi:10.1001/jamaoncol.2020.2169

This cohort study examines the safety and efficacy of immune checkpoint inhibitor rechallenge in patients with metastatic renal cell carcinoma.

Changes in Opioid Prescribing Patterns Among Generalists and Oncologists for Medicare Part D Beneficiaries From 2013 to 2017

Abstract Full Text
free access
JAMA Oncol. Published online May 29, 2020. doi:10.1001/jamaoncol.2020.2211

This cross-sectional study analyzed Medicare Part D prescriber files to determine changes in opioid prescribing patterns among oncologists and generalists between 2013 and 2017, during the opioid epidemic.

May 28, 2020
Original Investigation

Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial

Abstract Full Text
JAMA Oncol. Published online May 28, 2020. doi:10.1001/jamaoncol.2020.1260

This interventional clinical trial examines the safety and tolerability of osimertinib and bevacizumab combination treatment and assesses the 12-month progression-free survival of the combination in patients with metastatic EGFR-mutant lung cancers.

JAMA Oncology Clinical Challenge

Brain Lesion in the Setting of Chronic Rituximab Treatment

Abstract Full Text
has active quiz
JAMA Oncol. Published online May 28, 2020. doi:10.1001/jamaoncol.2020.0160

A 75-year old woman with a history of follicular lymphoma and breast cancer presents with gradual vision loss and confusion; magnetic resonance imaging reveals hyperintensity in the left occipital and temporal lobes. What is your diagnosis?

Viewpoint

Neoadjuvant Treatment for Patients With Localized Pancreatic Adenocarcinoma: Are We There Yet?

Abstract Full Text
JAMA Oncol. Published online May 28, 2020. doi:10.1001/jamaoncol.2020.0562

This Viewpoint advocates for increased use of neoadjuvant therapy in the treatment of localized pancreatic adenocarcinoma.

Comment & Response

Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer

Abstract Full Text
JAMA Oncol. Published online May 28, 2020. doi:10.1001/jamaoncol.2020.1513

Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer

Abstract Full Text
JAMA Oncol. Published online May 28, 2020. doi:10.1001/jamaoncol.2020.1516

Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer—Reply

Abstract Full Text
JAMA Oncol. Published online May 28, 2020. doi:10.1001/jamaoncol.2020.1518
May 27, 2020
Research Letter

Screening for COVID-19 in Asymptomatic Patients With Cancer in a Hospital in the United Arab Emirates

Abstract Full Text
open access has active quiz
JAMA Oncol. Published online May 27, 2020. doi:10.1001/jamaoncol.2020.2548

This case series examines the results of implementing a universal microbiologic screening strategy for asymptomatic patients with cancer for coronavirus disease 2019 at 1 institution in the United Arab Emirates.

Viewpoint

Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19

Abstract Full Text
free access has active quiz
JAMA Oncol. Published online May 27, 2020. doi:10.1001/jamaoncol.2020.2493

This Viewpoint suggests a new dosage for pembrolizumab treatment that could decrease patients’ exposure risk to COVID-19.

May 21, 2020
Original Investigation

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. Published online May 21, 2020. doi:10.1001/jamaoncol.2020.1024

This randomized clinical trial examines the effect of programmed cell death 1 immune checkpoint inhibition with nivolumab on overall survival for patients with recurrent glioblastoma.

Research Letter

Trends of Clinician Adherence to Evidence-Based Recommendations for Multidisciplinary Oncology Care for Patients With Esophageal Cancer

Abstract Full Text
JAMA Oncol. Published online May 21, 2020. doi:10.1001/jamaoncol.2020.1065

This cohort study examines national rates of neoadjuvant dual-agent chemotherapy and radiation followed by surgery in patients with locally advanced esophageal carcinoma after a randomized clinical trial demonstrated a survival advantage.

Viewpoint

How (or Do) People “Think” About Cancer Risk, and Why That Matters

Abstract Full Text
JAMA Oncol. Published online May 21, 2020. doi:10.1001/jamaoncol.2020.0170

This Viewpoint highlights the importance of understanding the sources and variations in people’s notions of cancer risk.

Editorial

Results From the CheckMate 143 Clinical Trial: Stalemate or New Game Strategy for Glioblastoma Immunotherapy?

Abstract Full Text
JAMA Oncol. Published online May 21, 2020. doi:10.1001/jamaoncol.2020.0857
Comment & Response

Value of Oncology Pharmacists in the Oncology Health Care Workforce

Abstract Full Text
JAMA Oncol. Published online May 21, 2020. doi:10.1001/jamaoncol.2020.1288

Value of Oncology Pharmacists in the Oncology Health Care Workforce—Reply

Abstract Full Text
JAMA Oncol. Published online May 21, 2020. doi:10.1001/jamaoncol.2020.1291
Correction

Change in License Type and Error in Figure 1

Abstract Full Text
free access
JAMA Oncol. Published online May 21, 2020. doi:10.1001/jamaoncol.2020.1749
May 20, 2020
Viewpoint

Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment

Abstract Full Text
has active quiz
JAMA Oncol. Published online May 20, 2020. doi:10.1001/jamaoncol.2020.2367

This Viewpoint discusses the challenges that arise for patients with cancer who are undergoing immune-engaging therapeutic treatment during the coronavirus disease 2019 (COVID-19) pandemic.

May 14, 2020
Original Investigation

Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation–Positive Non–Small Cell Lung Cancer: A Multicenter Phase 2 Trial

Abstract Full Text
JAMA Oncol. Published online May 14, 2020. doi:10.1001/jamaoncol.2020.1250

This single-arm, multicenter phase 2 trial investigates the efficacy and safety of low-dose erlotinib in elderly or frail patients with EGFR mutation–positive non–small cell lung cancer.

Brief Report

Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis

Abstract Full Text
JAMA Oncol. Published online May 14, 2020. doi:10.1001/jamaoncol.2020.1046

This systematic review and meta-analysis evaluates the association of immune checkpoint inhibitor treatment with overall response rate, disease control rate, overall survival, and progression-free survival in patients with microsatellite instability-high cancers.

Research Letter

Association of Medicaid Expansion Under the Patient Protection and Affordable Care Act With Non–Small Cell Lung Cancer Survival

Abstract Full Text
JAMA Oncol. Published online May 14, 2020. doi:10.1001/jamaoncol.2020.1040

This cohort study uses Surveillance, Epidemiology, and End Results data to assess if Medicaid expansion is associated with improved population-level survival in patients with non–small cell lung cancer.

Review

Clinical Application of Computational Methods in Precision Oncology: A Review

Abstract Full Text
JAMA Oncol. Published online May 14, 2020. doi:10.1001/jamaoncol.2020.1247

This review evaluates best practices for developing and assessing the clinical utility of predictive computational methods in oncology.

Viewpoint

Hippocampal-Sparing Radiotherapy for Patients With Glioblastoma and Grade II-III Gliomas

Abstract Full Text
JAMA Oncol. Published online May 14, 2020. doi:10.1001/jamaoncol.2020.0164

This Viewpoint advocates for the consideration of hippocampal-sparing radiotherapy in patients with gliomas to mitigate treatment-related adverse events.

Comment & Response

Shortlist of Quality Indicators for End-of-Life Cancer Care

Abstract Full Text
JAMA Oncol. Published online May 14, 2020. doi:10.1001/jamaoncol.2020.1159

Shortlist of Quality Indicators for End-of-Life Cancer Care—Reply

Abstract Full Text
JAMA Oncol. Published online May 14, 2020. doi:10.1001/jamaoncol.2020.1162
May 13, 2020
Research Letter

COVID-19 in Children With Cancer in New York City

Abstract Full Text
free access has active quiz
JAMA Oncol. Published online May 13, 2020. doi:10.1001/jamaoncol.2020.2028

This cross-sectional study assesses the risk associated with Coronavirus Disease 2019 for pediatric patients with cancer.

May 7, 2020
Original Investigation

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study

Abstract Full Text
open access
JAMA Oncol. Published online May 7, 2020. doi:10.1001/jamaoncol.2020.0910

This phase 2 randomized clinical trial evaluates the outcomes of combined immune checkpoint inhibition plus best supportive care vs best supportive care alone for patients with advanced colorectal cancer.

Brief Report

Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial

Abstract Full Text
JAMA Oncol. Published online May 7, 2020. doi:10.1001/jamaoncol.2020.1052

This double-blinded, randomized, placebo-controlled clinical trial evaluates the utility of olanzapine for treating chronic nausea/vomiting in patients with advanced cancer.

Research Letter

Incidence of Opioid-Associated Deaths in Cancer Survivors in the United States, 2006-2016: A Population Study of the Opioid Epidemic

Abstract Full Text
JAMA Oncol. Published online May 7, 2020. doi:10.1001/jamaoncol.2020.0799

This study analyzes the incidence of opioid-associated deaths in cancer survivors vs the general population in the US from 2006 through 2016 using National Center for Health Statistics death certificate data.

Association of Mandatory-Access Prescription Drug Monitoring Programs With Opioid Prescriptions Among Medicare Patients Treated by a Medical or Hematologic Oncologist

Abstract Full Text
JAMA Oncol. Published online May 7, 2020. doi:10.1001/jamaoncol.2020.0804

This cohort study examines the association between prescription drug monitoring program mandates with and without a cancer exemption and the percent of oncologists’ patients with any opioid prescription covered by Medicare Part D.

Viewpoint

The Case for Health Reform—The Oncologist’s Perspective

Abstract Full Text
JAMA Oncol. Published online May 7, 2020. doi:10.1001/jamaoncol.2020.0568

This Viewpoint makes the case for health reform in the United States and calls on oncologists and other physicians to share their experiences, participate in the conversation, and help guide principles of reform.

Palliative Care for Patients With Cancer in the COVID-19 Era

Abstract Full Text
free access has active quiz
JAMA Oncol. Published online May 7, 2020. doi:10.1001/jamaoncol.2020.1938

This Viewpoint discusses the considerations and challenges affecting the palliative care specialty and delivery of palliative care in the COVID-19 era, as well as potential solutions.

Editorial

Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancer—Fact or Fiction?

Abstract Full Text
JAMA Oncol. Published online May 7, 2020. doi:10.1001/jamaoncol.2020.0504
Invited Commentary

Managing Cancer Pain During the Opioid Epidemic—Balancing Caution and Compassion

Abstract Full Text
JAMA Oncol. Published online May 7, 2020. doi:10.1001/jamaoncol.2020.0779
Cancer Care Chronicles

Cancer and Coronavirus Disease 2019 (COVID-19)—Facing the “C Words”

Abstract Full Text
free access has active quiz
JAMA Oncol. Published online May 7, 2020. doi:10.1001/jamaoncol.2020.1848

This essay discusses similarities between a doctor’s experiences with diagnoses of cancer and coronavirus disease 2019 (COVID-19).

Comment & Response

Determining the Appropriate Risk-Adapted Screening Age for Familial Breast Cancer

Abstract Full Text
JAMA Oncol. Published online May 7, 2020. doi:10.1001/jamaoncol.2020.0286

Determining the Appropriate Risk-Adapted Screening Age for Familial Breast Cancer—Reply

Abstract Full Text
JAMA Oncol. Published online May 7, 2020. doi:10.1001/jamaoncol.2020.0292

De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ

Abstract Full Text
JAMA Oncol. Published online May 7, 2020. doi:10.1001/jamaoncol.2020.0816

De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ—Reply

Abstract Full Text
JAMA Oncol. Published online May 7, 2020. doi:10.1001/jamaoncol.2020.0819
×